Moffitt Cancer Center Begins Phase I Clinical Trial of New Immunotherapy

April 9, 2014 Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective …

Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma

April 4, 2014 Amgen today announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). Results showed that, while the primary end point of …

Amgen’s Talimogene Laherparepvec Reduced Size Of Melanoma Tumors In New Phase 3 Retrospective Analysis

Data Showed Tumor Shrinkage in Both Injected and Metastasized Tumors Results from Amgen’s Investigational Oncolytic Immunotherapy Presented Today at the Society for Surgical Oncology Congress in Phoenix March 14, 2014 Amgen today announced findings from a pre-specified retrospective analysis of patients with metastatic melanoma that showed talimogene laherparepvec reduced the size of injected tumors and also non-injected tumors that had …

Genocea Biosciences Announces Collaboration to Characterize T Cell Responses to Cancer Antigens

March 3, 2014 Genocea Biosciences, Inc., a company pioneering novel T cell vaccines and immunotherapies, today announced a joint research collaboration with Dana-Farber Cancer Institute and Harvard Medical School to characterize anti-tumor T cell responses in melanoma patients. This collaboration extends the use of the company’s proprietary ATLAS™ platform for the rapid discovery of T cell antigens to cancer immunotherapy approaches. “ATLAS™ has proven …